Purchase Short-Term Access

Review: Rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes

Prakash Deedwania, MD

Annals of Internal Medicine 2011;155:JC2-12. doi:10.7326/0003-4819-155-4-201108160-02012

Purchase Online access to this article for 24 hours

Annals of Internal Medicine

Forgot Your Password?

to gain full access to the content and tools.

Learn more about subscription options

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username* (Required)

Email Address* (Required)